Regadenoson Pharmacokinetics and Tolerability in Subjects With Impaired Renal Function
Authors:
- 1 July 2007
- journal article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 47 (7) , 825-833
Abstract
The authors have investigated the pharmacokinetics and tolerability of regadenoson, a selective A2Aadenosine receptor agonist for use in drug‐stressed myocardial perfusion imaging in subjects with varying degrees of renal function. Sixteen subjects with different creatinine clearance values (range: 15–132 mL/min) received a single intravenous bolus dose of 400 μg regadenoson. A population pharmacokinetic model was developed to describe the pharmacokinetics of regadenoson in these subjects. Regadenoson elimination half‐life was prolonged with decreasing renal function. However, maximum plasma concentrations, number, or severity of adverse events did not differ significantly between the subjects. Heart rate increased in all subjects after regadenoson injection but returned to normal within 150 minutes. There were no blood pressure pattern differences with respect to renal function. Results from this study do not indicate that dose adjustments are necessary when subjects with decreased renal function are administered the clinically relevant dose of 400 μg regadenoson.Keywords
This publication has 10 references indexed in Scilit:
- Tachycardia Caused by A2A Adenosine Receptor Agonists Is Mediated by Direct Sympathoexcitation in Awake RatsThe Journal of Pharmacology and Experimental Therapeutics, 2006
- A3 Adenosine Receptor Ligands: History and PerspectivesMedicinal Research Reviews, 2000
- A2A-Adenosine Receptor Reserve for Coronary VasodilationCirculation, 1998
- The A2A Adenosine Receptor Mediates Coronary VasodilationThe Journal of Pharmacology and Experimental Therapeutics, 1998
- Xpose—an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEMComputer Methods and Programs in Biomedicine, 1998
- Adenosine and Adenosine Receptors in the Cardiovascular System: Biochemistry, Physiology, and PharmacologyThe American Journal of Cardiology, 1997
- Cardiovascular purinoceptorsPhysiological Reviews, 1990
- The cardiac effects of adenosineProgress in Cardiovascular Diseases, 1989
- Hysteresis of the ventricular paced QT interval in response to abrupt changes in pacing rateCardiovascular Research, 1988
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976